Status:

TERMINATED

Optimum Immunosuppression in Renal Transplant Recipients.New Onset Diabetes After Transplantation

Lead Sponsor:

Armando Torres Ramírez

Conditions:

Diabetes Mellitus, Adult-Onset

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

New onset diabetes after renal transplantation (NODAT) is a common and severe complication negatively influencing graft and patient survival. Cyclosporine (CsA) and Tacrolimus are the basis of modern ...

Detailed Description

New onset diabetes after renal transplantation (NODAT) is a common and severe complication negatively influencing graft and patient survival. CsA and Tacrolimus are the basis of modern immunosuppressi...

Eligibility Criteria

Inclusion

  • Primary renal transplant recipients with end stage renal disease
  • No prior history of diabetes mellitus before transplant
  • Absence of Immunologic risk defined by the investigator criterion and Panel Reactive Antibody (PRA) \< 50%
  • Absence of severe infection and hepatitis C or B infection
  • Efficient contraception in women during the study
  • Additionally must meet one of these "Metabolic Criteria
  • Recipient age \>or =60 or
  • Recipient age between 45 and 59 years and at least one of the following metabolic criteria: Prior to transplantation Triglycerides (TGS) \>200mg/dl or the combination of a body mass index (BMI)\> 27 and Triglycerides\>150 mg/dl or the combination of HDL-cholesterol\<40 mg/dl for men or \<50 mg/dl for women and Triglycerides \>150 mg/dl.

Exclusion

  • Patients with type I or II diabetes prior to transplantation defined by the American Diabetes Association (ADA) criteria
  • Recipient age under 45
  • Patients receiving a second renal transplant
  • Patients with high immunological risk or PRA (panel reactive antibody level) \>or =50%
  • Severe infection or hepatitis C or B infection.
  • Dual renal transplant or double transplant with any other organ.

Key Trial Info

Start Date :

February 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2015

Estimated Enrollment :

134 Patients enrolled

Trial Details

Trial ID

NCT01002339

Start Date

February 1 2010

End Date

June 1 2015

Last Update

October 22 2024

Active Locations (10)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (10 locations)

1

Antonio Osuna

Granada, Andalusia, Spain, 18014

2

Domingo Hernández

Málaga, Andalusia, Spain, 29010

3

Carlos Gómez Alamillo

Santander, Cantabria, Spain, 39008

4

Juan Manuel Díaz

Barcelona, Catalonia, Spain, 08025